U.S., Jan. 31 -- ClinicalTrials.gov registry received information related to the study (NCT06801886) titled 'Silymarin's Advantage on Graft Effectiveness' on Jan. 24.
Brief Summary: The study examines the impact of silymarin supplementation during the early post-transplant period, administering 900 g daily for 30 days under standard treatment. Subsequently, we investigate its impact on graft function, as measured by eGFR (CKD-EPI equation), UACR or UPCR, the development of dnDSA, rejection changes, and histological changes in the 3-month biopsy protocol. At the same time, we will investigate the effect of silymarin on metabolic complications-PTDM, DLP, disorders of calcium-phosphate metabolism, and arterial hypertension in the post-transpl...